Educational Activities Archives

Designed specifically for peer professionals and related helpers, this 90-minute webinar focuses on effective ways to support individuals engaged in treatment for opioid, stimulant, and other substance use disorders. Participants will explore the unique role of peer-based support, including how to build trust, encourage treatment engagement, reinforce recovery goals, and navigate boundaries while working alongside clinical providers. Attendees will explore negative biases and myths regarding individuals treated with medications for opioid use disorder. Practical tools and real-world scenarios will help attendees strengthen their skills in supporting sustained engagement and long-term recovery outcomes.

Understanding addiction is essential to successfully addressing it. In this overview of substance use disorders, we discuss the spectrum of use, neurobiological responses to substances, theories that explain the disorders, public health impact and epidemiology, comorbidity, and integrated care for this chronic condition.

Opioid use disorder (OUD) has highly effective FDA-approved medications for its treatment. This course reviews and compares pharmacological treatment options for individuals with OUD, including methadone, buprenorphine (sublingual and injectable formulations), and naltrexone (oral and long-acting intramuscular formulations). Current evidence for each medication is reviewed in detail, and studies comparing each are discussed. The purpose and goal of medications for OUD are reviewed, and different treatment models are presented. The course includes case vignettes in which medication options for OUD are considered.

This course discusses the importance of integrating opioid use disorder (OUD) pharmacotherapy into general medical settings, and describes models in primary care, emergency rooms, and hospitals where medications for OUD treatment are successfully included as standard care. Through reviews of OUD pharmacotherapy implementation in clinical practice, participants will learn how to adapt these strategies to their own settings. The course also introduces evidence-based counseling approaches to enhance motivation, treatment engagement, and sustained remission. Standard Medical Management (SMM) will be highlighted as an efficient, structured option readily incorporated into primary care. Participants are encouraged to adapt this information for use in their own clinical practices.

Stimulant use, including cocaine, methamphetamine and prescription stimulants, continues to be a growing and urgent public health concern. According to the 2024 National Survey on Drug Use and Health, 9 million people in the U.S. had used stimulants not as prescribed in the past year. Though opioids are often the focus of overdose conversations, stimulant-related overdose deaths reached an estimated 51,630 in 2024, while 59% of all overdoses from January 2021 through June 2024 involved a stimulant (Centers for Disease Control and Prevention, 2025). These trends underscore the critical need for effective treatment and engagement strategies. Several evidence-based behavioral therapies exist to help providers treat stimulant use disorder. This webinar will outline the clinical and administrative approaches to assess, treat and support people experiencing stimulant use disorder.

Mutual-help organizations (MHOs) such as Alcoholic Anonymous, SMART Recovery, LifeRing and many others, are ubiquitous across the United States and are found in small, medium, and large cities. They can be a valuable addition to treatment plans and extend the reach of the clinician by providing their patients with ongoing paths to recovery via crucial sober social support that has been found to confer valuable relapse prevention skills. This presentation provides education about the origin, types, scope, and theoretical orientation of a variety of MHOs, including new evidence for their clinical and public health utility, as well as evidence on why they are so helpful. Examples of proven clinical strategies to enhance involvement with MHOs during and following treatment will be provided including for those patients taking medications.